Abstract
Although uveitis is reported as a rare adverse event (AE) associated with dabrafenib/trametinib therapy or nivolumab, the occurrence of severe uveitis is extremely rare. We describe two cases of Vogt-Koyanagi-Harada (VKH)-like uveitis developing after the sequential administration of nivolumab and dabrafenib/trametinib therapy. Interestingly, both cases had HLA-DRB1*04:05, which is strongly associated with VKH disease, and achieved biologically complete remission after the treatment for uveitis. Our cases suggest a possible correlation between VKH-like uveitis as an AE and the clinical outcomes of sequential administration of nivolumab and dabrafenib/trametinib therapy for the treatment of advanced melanoma.
Keywords:
Vogt-Koyanagi-Harada disease-like uveitis; advanced melanoma; immune-related adverse events; immunotherapy; molecular-targeting therapy.
© 2018 Japanese Dermatological Association.
MeSH terms
-
Adult
-
Aged
-
Antibodies, Monoclonal / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
-
Choroid / diagnostic imaging
-
Choroid / pathology
-
Female
-
Glucocorticoids / pharmacology
-
Glucocorticoids / therapeutic use
-
HLA-DRB1 Chains / blood*
-
HLA-DRB1 Chains / immunology
-
Humans
-
Imidazoles / adverse effects
-
Magnetic Resonance Imaging
-
Male
-
Melanoma / drug therapy*
-
Nivolumab
-
Oximes / adverse effects
-
Pyridones / adverse effects
-
Pyrimidinones / adverse effects
-
Skin Neoplasms / drug therapy*
-
Treatment Outcome
-
Uveomeningoencephalitic Syndrome / blood
-
Uveomeningoencephalitic Syndrome / chemically induced*
-
Uveomeningoencephalitic Syndrome / drug therapy
-
Uveomeningoencephalitic Syndrome / immunology
-
Visual Acuity / drug effects
Substances
-
Antibodies, Monoclonal
-
Glucocorticoids
-
HLA-DRB1 Chains
-
HLA-DRB1*04 antigen
-
Imidazoles
-
Oximes
-
Pyridones
-
Pyrimidinones
-
Nivolumab
-
trametinib
-
dabrafenib